Emphasys on the Block after FDA Panel Rejection

Emphasys Medical, following negative recommendation from an FDA panel, put itself up for sale.

The end is near for Emphasys Medical Inc. At the end of March, the company's ongoing business and assets will be put up for auction, serving as an disappointing end to the company's nine-year effort to get its Zephyr endobronchial valve to market. But although Emphasys likely will be gone, company executives hope the buyer will push forward, putting enough muscle behind the device to get the Food & Drug Administration’s approval.

The sale may be seen as a failure on the part of company management, but president and chief executive officer...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip